Prevalence & Prescription: Prescribing Practices of Clozapine in Australia between 2005 & 2010

Vella, SC and Pai, NB (2012) Prevalence & Prescription: Prescribing Practices of Clozapine in Australia between 2005 & 2010. [Journal (On-line/Unpaginated)]

Full text available as:

PDF - Published Version
Available under License Creative Commons Attribution No Derivatives.



Clozapine is an anti-psychotic used to treat refractory schizophrenia. This study reviews the rates of clozapine prescription for refractory schizophrenia in a region of Australia and compares the prescribing patterns to the estimated prevalence rates of refractory schizophrenia in the region. Utilising a pharmacoepidemiological approach; the results indicated that only 8.4% of the individuals estimated to be suffering from refractory schizophrenia in the region were prescribed clozapine between 2005 and 2010, with only 4.1% continuing clozapine to the conclusion of the study. In conclusion it is evident that clozapine is widely under-prescribed in this area of Australia.

Item Type:Journal (On-line/Unpaginated)
Keywords:Clozapine; Treatment-resistant schizophrenia; Prevalence rates; Australia
JOURNALS > Online Journal of Health and Allied Sciences
ID Code:8871
Deposited By: Kakkilaya Bevinje, Dr. Srinivas
Deposited On:04 May 2013 23:04
Last Modified:04 May 2013 23:04

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

1. Capuano B, Crosby IT, Lloyd EJ. Schizophrenia: Genesis, receptorology, and current therapeutics. Current Medicinal Chemistry. 2002;9:521-548.

2. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin. 1997;23(4):663-674.

3. Semiz UB, cetin M, Basoglu C, Ebrinc S, Uzun O, Herken H, Balibey H, Algul A, Ates A. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2007;31:1330-1336.

4. Angermyer MC, Loffler W, Muller P, Schulze B, Priebe S. Patients’ and relatives’ assessment of clozapine treatment. Psychological Medicine. 2001;31:509-517.

5. Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? Journal of Psychopharmacology. 2009;23(8):957-965.

6. Kelly DL, Kreyenbuhl J, Buchanan RW, Malhotra AK. Why not clozapine? Clinical Schizophrenia. 2007;1:92-95.

7. Henneen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophrenia Research 2005;73:139-145.

8. Young CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine. Schizophrenia Bulletin 1998;24(3): 381-390.

9. Reznik I, Volchek L, Mester R, Kotler M, Sarova-Pinhas I, Spivak B, Weizman A. Myotoxicity and neurotoxicity during clozapine treatment. Clinical Neuropharmacology 2000;23(5):276-280.

10. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists attitude towards and knowledge of schizophrenia treatment. Journal of Psychopharmacology. 2010;24(7):965-971.

11. Wheeler A, Humberstone V, Robinson G. Trends in anti-psychotic prescribing in schizophrenia in Auckland. Australasian Journal of Psychiatry 2006;14(2):169-174.

12. Marder SR. Can clinical practice guide a research agenda? Schizophrenia Bulletin. 2002;28(1):127-129.

13. Conley RR, Kelly DL, Lambert TJ, Love RC. Comparison of clozapine use in Maryland and in Victoria Australia. Psychiatric Services. 2005;56(3):320-323.

14. Fayek M, Flowers C, Signorelli D, Simpson G. Psychopharmacology: underuse of evidence-based treatments in psychiatry. Psychiatric Services. 2003;54(11):1453-1456.

15. Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Australian and New Zealand Journal of Psychiatry. 2002;37:55-61.

16. Weinbrenner S, Assion HJ, Stargardt T, Busse R, Juckel G, Gericke CA. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund. Pharmacopsychiatry 2008;41:1-6.

17. Drew LRH, Griffiths KM, Hodgson DM. A five year follow-up study of the use of clozapine in community practice. Australian and New Zealand Journal of Psychiatry 2002;36:780-786.


Repository Staff Only: item control page